The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer

Although cyclin-dependent kinase (CDK) 4/6 inhibitors have exhibited remarkable results for patients with estrogen receptor (ER)–positive breast cancer in clinical trials, the mechanism of CDK4/6 inhibitor resistance remains unclear. Thus, this study aimed to investigate the mechanism of CDK4/6 inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Iida, Masafumi, Nakamura, Misato, Tokuda, Emi, Toyosawa, Daichi, Niwa, Toshifumi, Ohuchi, Noriaki, Ishida, Takanori, Hayashi, Shin-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690670/
https://www.ncbi.nlm.nih.gov/pubmed/31448056
http://dx.doi.org/10.18632/oncotarget.27127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690670/
https://www.ncbi.nlm.nih.gov/pubmed/31448056
http://dx.doi.org/10.18632/oncotarget.27127

Ejemplares similares